All In Biotech

Drug Trial Radar · NCT04297683

HEALEY ALS Platform Trial - Master Protocol

HEALEY ALS Platform Trial

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jun 14, 2020

Primary completion

Jul 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Merit E. Cudkowicz, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Massachusetts General Hospital
First posted
Mar 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • ZilucoplanDrug

    Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight

  • VerdiperstatDrug

    Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily

  • CNM-Au8Drug

    Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily

  • PridopidineDrug

    Drug: Pridopidine Administration: Oral Dose: 45mg twice daily

  • SLS-005 TrehaloseDrug

    Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly

  • ABBV-CLS-7262Drug

    Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2

  • DNL343Drug

    Drug: DNL343 Administration: Oral Dose: Once per day

  • NUZ-001Drug

    Drug: NUZ-001. Administration: Oral. Dose: Once per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease ProgressionTime frame: 36 Weeks

Locations

81 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • UC San Diego

    La Jolla, California

  • Loma Linda University Health

    Loma Linda, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California, Irvine

    Orange, California

  • Forbes Norris MDA/ALS Research Center, California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Hospital for Special Care

    New Britain, Connecticut

  • Yale University

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • George Washington University

    Washington D.C., District of Columbia

  • Nova Southeastern University

    Davie, Florida

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • University of South Florida

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University Health

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Fairway, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Ochsner Health System

    New Orleans, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • University of Massachusetts Medical School

    North Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • Spectrum Health/Corewell Health

    Grand Rapids, Michigan

  • Essentia Health

    Duluth, Minnesota

  • University of Minnesota Medical School

    Minneapolis, Minnesota

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.